Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | CNR1 | P21554 | 2/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
| ▸ | CNR2 | P34972 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28820388 | 0.97 | ALDH1A1 (0.68) | ALDH1A1CNR1TRPV1CNR2PKM | |
| SCHEMBL17397496 | 0.95 | CNR1 (0.68) | ALDH1A1CNR1TRPV1CNR2PKM | |
| SCHEMBL17397500 | 0.95 | CNR1 (0.68) | ALDH1A1CNR1TRPV1CNR2PKM | |
| SCHEMBL4901981 | 0.92 | MEN1 (0.63) | ALDH1A1CNR1TRPV1CNR2PKM | |
| SCHEMBL27909130 | 0.88 | ALDH1A1 (0.72) | ALDH1A1CNR1TRPV1CNR2PKM | |
| SCHEMBL11873499 | 0.86 | ALDH1A1 (0.70) | ALDH1A1CNR1TRPV1CNR2PKM | |
| SCHEMBL933945 | 0.86 | CNR1 (0.76) | ALDH1A1CNR1TRPV1CNR2NPC1 | |
| SCHEMBL23000078 | 0.85 | ALDH1A1 (0.68) | ALDH1A1CNR1TRPV1CNR2PKM | |
| SCHEMBL16762031 | 0.85 | CNR1 (0.82) | ALDH1A1CNR1CNR2 | |
| SCHEMBL27909118 | 0.85 | ALDH1A1 (0.72) | ALDH1A1CNR1TRPV1CNR2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-11311619-B2 | Integrin activator vaccine compositions | 7 Hills Pharma Inc. and Texas Heart Institute (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3104867-B1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 Hills Pharma LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210023207-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | 7 Hills Pharma LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | 7 Hills Pharma LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | 7 Hills Pharma LLC (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | 7 Hills Pharma LLC (US) | 2020-02-20 | — | — | US | disclosed |
| US-20190343952-A1 | METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | 7 Hills Pharma LLC (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3288585-A2 | NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS | 7 HILLS INTERESTS, LLC (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3104867-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS INTERESTS, LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160339098-A1 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | 7 HILLS PHARMA INC. | 2016-11-24 | — | — | US | disclosed |
| WO-2016176400-A2 | NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS | 7 HILLS INTERESTS LLC (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2015123447-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA, LLC (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311619-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | ALDH1A1 3698/4885CNR1 3147/4885TRPV1 721/4885 |
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | CD47, ITGA1, ITGA2B | ALDH1A1 2560/4885CNR1 3927/4885TRPV1 2327/4885 |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | CD47, ITGA1, ITGAM | ALDH1A1 2403/4885CNR1 4188/4885TRPV1 2249/4885 |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA2 | ALDH1A1 3479/4885CNR1 3597/4885TRPV1 2326/4885 |
| US-20190343952-A1 | METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | ITGAM, ITGA2B, ITGA2 | ALDH1A1 3479/4885CNR1 3597/4885TRPV1 2326/4885 |
| US-20210023207-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | ITGA2B, ITGAM, ITGAV | ALDH1A1 4069/4885CNR1 3135/4885TRPV1 732/4885 |
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | CXCL12, ITGB3, ITGB7 | ALDH1A1 1083/4885CNR1 3580/4885TRPV1 4167/4885 |
| US-20160339098-A1 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | CD4, CD274, ICOS | ALDH1A1 3675/4885CNR1 1775/4885TRPV1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.